Naloxone Availability, Testing Drugs for Potency, and Solitary Use: Unpacking the Determinants of Overdose Prevention Behaviors
Carl A. Latkin(Johns Hopkins University), Oluwaseun Falade‐Nwulia(Johns Hopkins University), Lauren Dayton(Johns Hopkins University), Melissa Davey‐Rothwell(Johns Hopkins University), Grace Yi(Johns Hopkins University), Haley Bonneau(Johns Hopkins University), Leane Santos-Silva(Johns Hopkins University)
Cited by 0
Related Papers
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
|Annals of Internal Medicine|2017|694
The neglected health of international migrant workers in the COVID-19 epidemic
|The Lancet Psychiatry|2020|402
Adverse interactions between antifungal azoles and vincristine: review and analysis of cases
|Mycoses|2011|159
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
|UNC Libraries|2020|111